Aspen Pharmacare Holdings Limited (APNHY)
APNHY Stock Price Chart
Explore Aspen Pharmacare Holdings Limited interactive price chart. Choose custom timeframes to analyze APNHY price movements and trends.
APNHY Company Profile
Discover essential business fundamentals and corporate details for Aspen Pharmacare Holdings Limited (APNHY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
5 Apr 2010
Employees
8.87K
Website
https://www.aspenpharma.comCEO
Stephen Bradley Saad BCom,
Description
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.
APNHY Financial Timeline
Browse a chronological timeline of Aspen Pharmacare Holdings Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Mar 2026
Earnings released on 3 Sept 2025
Earnings released on 3 Mar 2025
EPS came in at $0.35 , while revenue for the quarter reached $1.18B .
Dividend declared on 4 Sept 2024
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 8 Oct 2024.
Earnings released on 3 Sept 2024
EPS came in at $0.26 falling short of the estimated $0.57 by -54.42%, while revenue for the quarter reached $1.30B , beating expectations by +0.03%.
Earnings released on 14 Mar 2024
EPS came in at $0.28 , while revenue for the quarter reached $1.15B , beating expectations by +8.95%.
Dividend declared on 30 Aug 2023
A dividend of $0.18 per share was announced, adjusted to $0.18. The dividend was paid on 11 Oct 2023.
Earnings released on 30 Jun 2023
EPS came in at $0.31 falling short of the estimated $0.48 by -35.74%, while revenue for the quarter reached $1.15B , missing expectations by -1.70%.
Earnings released on 31 Dec 2022
EPS came in at $0.36 , while revenue for the quarter reached $1.13B .
Dividend declared on 2 Sept 2022
A dividend of $0.18 per share was announced, adjusted to $0.18. The dividend was paid on 11 Oct 2022.
Earnings released on 30 Jun 2022
EPS came in at $0.42 falling short of the estimated $0.48 by -10.96%, while revenue for the quarter reached $1.18B , missing expectations by -19.65%.
Earnings released on 31 Dec 2021
EPS came in at $0.46 , while revenue for the quarter reached $1.22B .
Dividend declared on 7 Sept 2021
A dividend of $0.18 per share was announced, adjusted to $0.18. The dividend was paid on 12 Oct 2021.
Earnings released on 30 Jun 2021
EPS came in at $0.19 falling short of the estimated $0.38 by -49.95%, while revenue for the quarter reached $664.60M , missing expectations by -49.37%.
Earnings released on 31 Dec 2020
EPS came in at $0.34 , while revenue for the quarter reached $1.27B .
APNHY Stock Performance
Access detailed APNHY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.